HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Phase 3 FeDeriCa and PHranceSCa Trial Overviews

February 26th 2021

Novel Agents for Late-Stage HER2+ MBC

February 26th 2021

Practical Advice for Toxicity Management in HER2+ MBC

February 19th 2021

Brain Metastases Therapy in Second-Line HER2+ MBC

February 19th 2021

Tucatinib Approved in Europe for Locally Advanced or Metastatic HER2+ Breast Cancer

February 12th 2021

February 12, 2021 - The European Commission has granted marketing authorization to tucatinib for use in combination with trastuzumab and capecitabine in the treatment of adult patients with HER2-positive, locally advanced or metastatic breast cancer who have previously received at least 2 HER2-targeted regimens

Sequencing Therapy in R/R HER2+ MBC

February 12th 2021

Newly FDA Approved Therapies: R/R HER2+ MBC

February 12th 2021

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

February 8th 2021

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Moving Metastatic Therapy to Early Stage Setting

February 5th 2021

Hormone Therapy in HER2+ Breast Cancer

February 5th 2021

Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer

February 3rd 2021

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

January 29th 2021

Adjuvant Systemic Therapy Data Updates

January 29th 2021

Metastatic Triple-Negative Breast Cancer

January 27th 2021

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

January 27th 2021

Metastatic Hormone-Receptor Positive Breast Cancer

January 27th 2021

Updated Data for Metastatic HER2+ Breast Cancer

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

January 25th 2021

Hurvitz Highlights Key Developments Made in Metastatic HER2+ Breast Cancer Paradigm

January 23rd 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.